MedTrace Logo

Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children

NCT07154992 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2025-09-12

No results posted yet for this study

Summary

Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper respiratory tract infections (URTIs) in a healthy paediatric population.

Conditions

Interventions

DIETARY_SUPPLEMENT

Probiotic - Lacticaseibacillus rhamnosus CRL1505

The probiotic product is provided in 2g sticks containing the strain Lacticaseibacillus rhamnosus CRL1505 at a concentration of ≥ 1.0E+8 CFU/g, with corn starch and maltodextrin as excipients.

DIETARY_SUPPLEMENT

Placebo

The placebo product is provided in 2g sticks of corn starch and maltodextrin.

Sponsors & Collaborators

  • Centro Sperimentale del Latte S.r.l.

    collaborator UNKNOWN

  • Bioithas SL

    lead INDUSTRY

Principal Investigators

  • Valentina Taverniti · Microbes & Health R&D Leader, Centro Sperimentale del Latte S.r.l.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-17
Primary Completion
2027-03-31
Completion
2027-04-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07154992 on ClinicalTrials.gov